Today: 1 May 2026
Ondas (ONDS) stock ends volatile week lower after fresh SEC filings flag share overhang
24 January 2026
2 mins read

Ondas (ONDS) stock ends volatile week lower after fresh SEC filings flag share overhang

New York, Jan 23, 2026, 21:11 EST — Market closed.

  • Ondas shares fell 3.5% on Friday, closing at $12.17 after a high-volume session.
  • The company filed paperwork for a potential resale of 1.62 million shares tied to the Sentry CS acquisition.
  • Ondas also disclosed an $8.4 million preferred stock financing at its Ondas Networks unit.

Ondas Inc shares ended Friday down 3.5% at $12.17, with roughly 79.5 million shares traded as the stock stayed choppy into the weekend.

A late-week SEC filing showed Ondas filed a prospectus supplement that allows certain stockholders to resell 1,622,607 shares from time to time, shares issued in connection with the company’s acquisition of Israel-based counter-drone firm Sentry CS Ltd.

That matters because a resale registration can hang over a stock even when the company is not selling new shares itself. The prospectus said Ondas will not receive proceeds from any such sales and set out a trading limit that caps aggregate selling by those holders to 10% of average daily volume; it also laid out a further payment under the Sentry deal due after a 120-day period from the Nov. 17 closing, including $2.5 million in cash and stock valued at $22.5 million (with flexibility to pay part in cash).

In a separate 8-K dated Jan. 23, Ondas disclosed an $8.4 million Series B preferred stock financing at its Ondas Networks subsidiary, consummated on Jan. 16. The filing said Ondas invested about $6.0 million and Charles & Potomac Capital about $2.0 million, with the preferred stock carrying an 8% annual dividend (payable only if declared) and convertible into Ondas Networks common stock at an initial $27.70 conversion price.

Sell-side commentary stayed active around the name. Stifel analyst Jonathan Siegmann raised his price target to $18 and kept a buy rating after last week’s investor day, saying the company’s targets were “nicely above our estimates” and that Stifel gained “greater appreciation of their differentiated approach to the military drone space.” TipRanks

At that investor day on Jan. 16, Ondas raised its 2026 revenue target to $170 million to $180 million and pointed to an estimated backlog of $65.3 million at Dec. 31, 2025. It also posted preliminary (unaudited) 2025 revenue ranges and said it expects to report full-year results in March.

The stock has remained sensitive to share-supply headlines since the company closed a $1 billion registered direct offering earlier this month, selling 19 million common shares and pre-funded warrants for up to 41.79 million shares, with additional warrants attached. Ondas estimated net proceeds of about $959.2 million and said the warrants, if fully exercised for cash, could raise additional proceeds, though it cautioned there is no assurance of exercise.

With U.S. markets shut for the weekend, traders head into Monday watching for follow-through in volumes and whether the resale registration translates into actual selling once liquidity returns.

But the downside case is straightforward: more stock hitting the market can pressure prices, and the Sentry purchase agreement still has a stock component later in the first quarter. Any abrupt slide can also cool appetite for warrant exercise and keep sentiment pinned to dilution math rather than operating results.

Next up is Ondas’ March update on 2025 results and the next scheduled Sentry-related payment once the 120-day period from the Nov. 17 closing rolls off in mid-March.

Stock Market Today

  • Avalyn Pharma Rings Nasdaq Opening Bell Highlighting Pulmonary Fibrosis Treatment Advances
    April 30, 2026, 6:32 PM EDT. Avalyn Pharma (Nasdaq: AVLN) marked a milestone by ringing the Opening Bell at Nasdaq MarketSite in Times Square. CEO Lyn Baranowski led the ceremony, spotlighting the company's efforts to develop optimized inhaled formulations of antifibrotic drugs. These medicines target pulmonary fibrosis, a rare and serious respiratory disease. Avalyn aims to transform treatment paradigms with these innovations. The event underscores Avalyn's focus on rare lung conditions and growing presence in the biotech sector.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
GE Vernova stock: Power-unit CEO exit lands days before earnings
Previous Story

GE Vernova stock: Power-unit CEO exit lands days before earnings

Merck (MRK) stock price slips into the weekend — what investors watch next week
Next Story

Merck (MRK) stock price slips into the weekend — what investors watch next week

Go toTop